Since the introduction of highly active antiretroviral therapies (ART) the prognosis for HIV-1 patients has improved immensely. However, approximately 25% of patients can experience a variety of inflammatory symptoms that are collectively known as immune reconstitution inflammatory syndrome (IRIS). Studying the etiology and immunopathology of IRIS has been hampered by the fact that the symptoms and associated opportunistic infections (OI) are highly varied. We hypothesized that there is a common mechanism underlying IRIS pathogenesis and investigated a patient group with IRIS related to different pathogens. Functional and phenotypic characterization of PBMC samples was performed by polychromatic flow cytometry following in vitro stimulation with relevant antigenic preparations. In most patients, IRIS events were characterized by the robust increase of pre-existing polyfunctional, highly differentiated effector CD4 + Tcell responses that specifically targeted the antigens of the underlying co-infection. T-cell responses to HIV-1 or other underlying infections were not affected and did not differ between IRIS and non-IRIS patients. These data suggest that patients with IRIS do not have a generalized T-cell dysfunction; instead, IRIS represents a dysregulated CD4 + Tcell response against residual OI antigen. These studies were registered at www.clinicaltrials.gov as #NCT00557570 and #NCT00286767.
Introduction
Immune reconstitution inflammatory syndrome (IRIS) is a severe clinical complication that manifests in approximately 25% of HIV-1 patients initiating highly active antiretroviral therapy (ART) 1 . Previous studies showed that the incidence of IRIS is higher in patients with advanced immunodeficiency who also have underlying opportunistic infections (OI) 2 . With ART becoming more widely available in populations with a high incidence of OIs, the occurrence of IRIS is likely to further increase in the near future. Thus, a better understanding of the immunopathology and identification of predictive biomarkers are of great clinical importance in order to develop targeted interventions.
Different types of IRIS have been identified, including "unmasking" IRIS, defined as a previously sub-clinical, undiagnosed OI occurring shortly after ART initiation, which cannot be explained by a de novo infection; "paradoxical" IRIS, defined as a worsening of a known condition for which the patient has been treated successfully (microbial cultures are often negative) 3, 4 ; and "autoimmune" IRIS, encompassing immune responses to self-antigens. This last category has received less attention in the literature, though there have been several reports of Graves' disease associated with IRIS [5] [6] [7] . In all three types, there is inflammation occurring during immune reconstitution that cannot be explained by drug toxicity or de novo infection. IRIS is largely a diagnosis of exclusion, but some criteria have been outlined by the AIDS Clinical Trials Group 8 , as well as the International Network for the study of HIV-associated IRIS (INSHI) 9, 10 .
The immunopathogenesis of IRIS remains unclear. IFN-γ-producing T-cells appear to be the main players driving the dysregulated inflammatory response 11 but these findings are not consistent with those of other groups 12, 13 . In a study of Cryptococcusassociated IRIS, paucity of immune responses prior to ART appeared to predispose to
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From immunocompromised patients who are ART-naïve at OI diagnosis 1 and those with low CD4 counts appear to be most susceptible to IRIS 2, 15, 16 . Other risk factors include high HIV-1 RNA levels pre-ART 2 , a more rapid initial HIV-1 RNA suppression 1,17 , a high OI-derived antigen load at the time of ART initiation 3,18 , a short time interval between diagnosis and/or treatment start of an OI and ART initiation 1, 3, 16 , and a low body-massindex 15 . Nonetheless, reports are not consistent, and it has been suggested that risk factors might differ by mode of IRIS presentation and etiology 13, 15 .
Most studies to date trying to elucidate potentially diagnostic risk factors and/or biomarkers of IRIS have focused on patient groups with a particular opportunistic infection, such as Mycobacterium tuberculosis 16, [19] [20] [21] , Mycobacterium avium and intracellulare complex 22 , Cryptococcus neoformans 3, 14, 18 , or CMV 12 . However, we hypothesized that there might be some common mechanisms underlying the development of IRIS in HIV-1 patients on ART, despite the highly variable clinical manifestations and variety of agents that can be associated with the syndrome.
We recently reported elevated frequencies of PD-1 + cells pre-ART, both within the CD4 + and CD8 + T-cell compartments 23 , showing evidence of antigenic stimulation and a propensity for Th1 cytokine production. It was unclear whether the increased T-cell activation was due to HIV-1, the IRIS-associated pathogen or other co-pathogens. We addressed this question using a cohort of HIV-1-infected IRIS patients with variable IRIS-causing OIs, and HIV-1-infection contemporary controls. In order to exclude the baseline CD4 + T-cell count and persistent HIV-1 viremia as factors influencing outcome, only patients with <100 CD4 + cells/μl at baseline and <50 HIV-1 RNA copies/ml after one year of treatment were included in the present study. We found that most IRIS patients manifest an upsurge of pre-existing Ag-specific CD4 + T-cell responses that are
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For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
Patients, Materials and Methods

Human Subjects and Sample Collection
67 HIV-1-infected subjects were enrolled and provided written informed consent at the Clinical Center of the National Institute of Allergy and Infectious Diseases, NIH, under an Institutional Review Board (IRB) approved protocol. Patient inclusion criteria have been described previously 24 . Briefly, all patients (1) were ART-naïve or had interrupted treatment for at least one year (n=4, plus n=2 who had previously received brief mono-or dual-therapy; one of these was an IRIS patient) with a viral rebound of >10,000 copies/ml, (2) had ≤ 100 CD4 + T-cells/μl at baseline, (3) suppressed their HIV-1 viral load to <500 copies/ml within one year of ART, and (4) had available PBMC samples taken pre-ART as well as after 1, 3, 6 and 12 months of ART. 19 patients developed IRIS episodes following commencement of ART, while 48 underwent uneventful immune reconstitution (Table 1) . IRIS was defined according to the AIDS Clinical Trials Group criteria 8 . The median time to IRIS was 1.4 months (IQR 0.9-2.6).
Baseline characteristics, use of non-nucleoside reverse-transcriptase inhibitors (NNRTI) or protease inhibitors (PI), and ethnicity distribution was comparable between the IRIS and non-IRIS groups; the frequency of co-infections was more elevated in IRIS patients (Table 1) . A subset of this cohort has been previously described in detail 24 .
Ethical Approval
All patients provided written informed consent prior to inclusion in accordance with the Declaration of Helsinki, and the study was performed according to an NIAID Institutional Review Board (IRB) approved protocol. 
Sample Preparation and Ag-stimulation
Cryopreserved PBMC were thawed in pre-warmed RPMI 1640, 10% FCS, 2mM
L-glutamine, 100 U/ml penicillin and 100 μ g/ml streptomycin (all from Gibco; this medium will hereafter be referred to as complete RPMI), in the presence of 20 μ g/ml benzonase nuclease (Novagen). Cells were rested in complete RPMI for 4-6 hours at 37°C, 5% CO 2 and either left unstimulated (mock control) or stimulated overnight in 200 μ l RPMI complete with different Ag-preparations (Table S1) 
Flow Cytometry
The reagent panel used in the present study was developed based on that described by Mahnke and Roederer 33 and is given in 
Data Analysis
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Data were analyzed using FlowJo (Tree Star), Pestle (by M Roederer) and SPICE 5.1 34 . The gating scheme is illustrated in Figure S3 . All cytokine measurements were background subtracted, taking into account the frequency of cells producing cytokines in the absence of antigenic stimulation (mock control). For the phenotypic analysis of Agspecific cells, only those samples with >10 cytokine-positive events and response magnitudes >3x that of the corresponding mock control were considered 34 .
Statistical Analysis
A two-tailed t-test was used to compare the proportion of individuals using steroids between the two patient groups. Nonparametric tests were used for all other analyses (SAS version 9.2). Changes from baseline within each group (paired differences) were evaluated using the Sign test. (Table S3) .
We first investigated the evolution of T-cell activation phenotypes and T-cell differentiation stages over the course of ART in IRIS and non-IRIS patients to determine whether these groups experienced differences in the overall reconstitution of T-cells during ART. Some of the phenotypes were previously investigated using different aliquots of a subset of these samples 23 . Here we significantly extended those studies, synchronizing samples to the IRIS event (Table S3) , and characterizing the pathogenspecific responses.
Even though statistically significant changes from baseline were observed over time in non-IRIS patients for many of the differentiation and activation markers investigated, comparable changes in IRIS patients were only rarely significant ( Figure   1A -D). Nevertheless, no statistically significant differences were detected between the overall activation status or T-cell subset distribution of CD4 + T-cells between IRIS and non-IRIS patients over the course of the study, except for the previously described elevated frequencies of PD-1 + cells pre-ART in eventual IRIS patients ( Figure 1A , C)
23
.
PD-1 + cells were also elevated pre-ART in CD8 + T-cells, while the only statistically significant differences at the time of IRIS (tp3) were observed in the frequencies of CD28 + and CD127 + cells, both of which were decreased in IRIS patients ( Figure 1B ).
Concordantly, a significantly more elevated proportion of highly differentiated (mainly T EM ) CD8 + T-cells was found in IRIS patients during and early after (tp3-4) clinical IRIS 1 1 diagnosis ( Figure 1D ). Together, these data confirm our previous observations that IRIS events are associated with highly activated T-cells.
Longitudinal Analysis of HIV-1-specific T-cell Responses During ART
We then set out to determine whether the HIV-1-specific T-cell response varied between the two patient groups. No significant differences were observed in terms of response magnitude, cytokine pattern or T-cell subset distribution within HIV-1 Gagspecific cells in either CD4 + ( 
Elevated CD4 + T-cell Responses to Relevant Ags in Patients With Mycobacterial-or
Fungal-associated IRIS Events
In order to obtain sufficient patient numbers to perform statistical analyses, the at clinical IRIS diagnosis and lasting throughout follow-up ( Figure 4E) . Overall, the magnitude of these responses was significantly increased during IRIS (tp3) compared to pre-ART (tp1) in most IRIS patients. Patients with "other IRIS" events included patients with MAC-associated IRIS whose PBMC were also tested for reactivity to TB, which explains the slight increase in CD4 + T-cell responses at tp3 as PBMC from MAC + individuals often show some measure of cross-reactivity to the TB Ag preparation (PPD)
used. Nevertheless, CD4 + T-cell responses to the IRIS-associated Ag were significantly higher at later timepoints (tp4-5; Figure 4E ) compared to non-associated mycobacterial or fungal Ags (other IRIS). The change from baseline (tp1) to tp3 was significantly different between patients with mycobacterial or fungal IRIS and non-IRIS patients (p=0.001), as well as other IRIS patients (p=0.012). Differences in changes from baseline to tp4 (p=0.002) and tp5 (p=0.009) were also found to be statistically significant between IRIS and non-IRIS patients.
Within patients with TB-associated IRIS, one patient exhibited elevated IRIS-Agspecific CD4 + T-cell responses at the sampling timepoint closest after clinical IRIS diagnosis (tp3), while in the other one the response was similar compared to pre-ART, rising again at a later time point ( Figure 4A ). This could be due to the timing of PBMC sampling (23 versus 6 days after the onset of IRIS event), which could be indicative of variation of biologic phenomena or tissue redistribution of TB-specific CD4 + T-cells.
The patient with Histoplasma-associated IRIS experienced concomitantly a MAC-IRIS event (cervical lymphadenopathy) and we cannot exclude that the IRIS occurrence was mainly driven by MAC. However, since fungal elements were detected in the biopsy material, this IRIS event had been formally classified as being driven by both
OIs. In this patient (Patient 56) the IRIS-associated Histoplasma-specific response 1 3 demonstrated but a 1.3-fold increase from pre-ART (tp1), whereas the MAC-associated response increased 14.8-fold in the same time span ( Figure 4D , Fig.5A ).
IRIS patients also demonstrated a significantly higher fraction of polyfunctional IFN-γ + cells during the IRIS episode than non-IRIS patients at a comparable sampling timepoint ( Figure 4F ), as well as a larger proportion of T EM cells ( Figure 4G ) among CD4 + T-cells reactive to the IRIS-associated Ag. However, no marked differences were observed in their activation phenotypes ( Figure 4H ).
Unusually Vigorous CD4 + T-cell Responses to the IRIS-associated Ag During IRIS Episodes
When we examined the evolution of CD4 + T-cell responses to different Ags in individual IRIS patients, we found dramatic increases only to the IRIS-associated Ag patient with JCV-associated unmasking IRIS did not produce any detectable JCV-specific CD4 + T-cell responses before the IRIS episode; proximally to the IRIS event, over 2% of total CD4 + T-cells were JCV-specific ( Figure S2C , open symbol at tp4: 2.3 months after clinical IRIS diagnosis). JCV-specific CD8 + T-cell responses demonstrated a vigorous increase directly after commencing ART that dampened early during the IRIS event and increased again thereafter ( Figure S2D ). This indicates an involvement of CD8 + T-cells in the pathogenesis of PML-IRIS although the increase in the CD8 + T-cell response during the IRIS event (tp3 to tp4) was lower in magnitude (2.1 fold) than the corresponding delayed CD4 + T-cell response (-0.3% to 2.1%). These data underscore a possible significant involvement of CD4 + T-cells in IRIS pathogenesis in some cases linked to viral pathogens.
Other IRIS-associated OI-specific T-cell responses were investigated (HBV, HHV-8, HPV, Strongyloides, VZV), but did not yield conclusive data.
Finally, proportionately more IRIS patients (26%) received glucocorticosteroid treatment directly pre-ART or within the first 6 months of ART compared to patients with uneventful immunoreconstitution (6.3%) (p=0.0223). Such treatment could reduce the overall magnitude of cytokine-responses measured. Notably, no significant changes were observed in HIV-1-specific CD8 + T-cell responses, while CD4 + T-cell responses were only moderately reduced in glucocorticosteroid-treated patients after 3 (p=0.013) and 12 months (p=0.035) of ART. This indicates that the differences observed between IRIS and non-IRIS patients were not the result of glucocorticosteroid treatment. , it has been proposed that the impairment of T REG to suppress proliferation of responder T-cells reported during IRIS events could at least in part explain the exuberant inflammatory T-cell responses observed in IRIS patients 22 . However, our
finding that T-cell responses against other pathogens than the IRIS-associated one were not significantly altered is inconsistent with this hypothesis.
In summary, our data suggest a common mechanism for the development of many IRIS occurrences that is independent of the associated opportunistic infection, whereby rapidly expanded Ag-specific CD4 + T-cells mount a polyfunctional inflammatory response to residual Ag of previously existing and inadequately controlled opportunistic infections once the HIV-1-induced functional inhibition is reversed by ART. For Representation of T-cell differentiation states. T-cell differentiation subsets were defined by expression of CD45RO ("RO"), CCR7 ("R7") and CD27 ("27"). to those Ags that a given patient was known to have been exposed to. Grey boxes highlight the first timepoint within 3 months of clinical manifestation of IRIS, while dashed lines separate pre-ART from on-ART samples. T-cell responses to IRISassociated Ags are indicated by bold lines. IRIS patients were selected for illustration if stimulation data were available for at least two Ags and at least four time-points. If two Ags fulfilled these criteria, all other stimulations with at least two data points were shown for that patient. Non-IRIS patients were selected according to the above criteria, as well as having known to be exposed to at least one of the Ags being tested for. 1 -tp1; 2 -tp2; 3 -tp3; 4 -tp4; 5 -tp5. Blood (print ISSN 0006-4971, online ISSN 1528-0020) , is published weekly by the American Society of
